A new male contraceptive: the Intra Vas Device

Information

  • Research Project
  • 6892228
  • ApplicationId
    6892228
  • Core Project Number
    R44HD046318
  • Full Project Number
    4R44HD046318-02
  • Serial Number
    46318
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/15/2004 - 20 years ago
  • Project End Date
    8/31/2007 - 17 years ago
  • Program Officer Name
    KAUFMAN, STEVEN
  • Budget Start Date
    9/2/2004 - 20 years ago
  • Budget End Date
    8/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/2/2004 - 20 years ago
Organizations

A new male contraceptive: the Intra Vas Device

DESCRIPTION (provided by applicant): With the world population continuing its steep rise, a serious need exists to increase the contraceptive options for men. Present male contraceptive technology relies on the condom and vasectomy; methods that are not acceptable to many men for cultural or religious reasons. Although the "male pill" may prove to be one solution for effective and reversible contraception when fully developed, there are likely to be many males who prefer non-hormonal products with fewer side effects. A silicone vas deferens device (the Intra Vas Device; IVD) has been under development for a number of years and has made considerable progress towards commercialization. The IVD has been designed to provide the same benefits as a vasectomy and be less traumatic, since IVD implantation does not require damaging the vas deferens to achieve vas obstruction. In addition, the IVD is expected to provide a simpler, faster and cheaper reversal procedure, compared to a vasectomy reversal. The IVD was shown to provide effective vas blockage in pilot clinical trials. IVD vas obstruction and complete recovery of sperm passage with IVD removal occurred in the primate. IVD safety was shown in two-year rat studies and in the pilot human studies. The advantages of the IVD over other vas devices tested previously (including silicone injected into the vas) are due to the IVD being preformed. IVD advantages include 1) it can be implanted and removed quickly by a relatively simple procedure, and 2) it can be fit to match the size of the vas lumen for better obstruction. Shepherd Medical has developed an improved IVD design in acute human studies and intends to perform all studies required to bring this refined IVD design to the market. The present project consists of two Specific Aims to ensure patient safety prior to human studies in Phase I1. The safety testing of this Phase I proposal includes: 1) in vitro evaluation of IVD sterilization methods prior to human implantation; and 2) in vitro evaluation of IVD mechanical performance with seven experiments. The successful outcome of this project will make human studies possible in Phase II.

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
  • Activity
    R44
  • Administering IC
    HD
  • Application Type
    4
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    703753
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    865
  • Ed Inst. Type
  • Funding ICs
    NICHD:703753\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SHEPHERD MEDICAL COMPANY
  • Organization Department
  • Organization DUNS
    147825876
  • Organization City
    MINNEAPOLIS
  • Organization State
    MN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    55415
  • Organization District
    UNITED STATES